What is GADOPICLENOL used for?

GADOPICLENOL (brand name Vueway) is a Other indicated for spine, and associated tissues), the body (head and neck.

What are the most common side effects of GADOPICLENOL?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for GADOPICLENOL. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is GADOPICLENOL the same as Vueway?

Vueway is a brand name for GADOPICLENOL. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

GADOPICLENOL

Q: How does GADOPICLENOL work?

GADOPICLENOL works through the following mechanism: 12.1 Mechanism of Action Gadopiclenol is a paramagnetic molecule (macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues..

Other

Brand names: Vueway

Intravenous

Mechanism of Action

12.1 Mechanism of Action Gadopiclenol is a paramagnetic molecule (macrocyclic non-ionic complex of gadolinium) that develops a magnetic moment when placed in a magnetic field. The magnetic moment alters the relaxation rates of water protons in its vicinity in the body, leading to an increase in signal intensity (brightness) of tissues.

Indications

spine

and associated tissues)

the body (head and neck

thorax

abdomen

pelvis

Contraindications

• 4 CONTRAINDICATIONS Vueway is contraindicated in patients with history of hypersensitivity reactions to Vueway. History of hypersensitivity reactions to Vueway ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Serious hypersensitivity reactions have occurred with GBCAs
1 Risk Associated with Intrathecal Use Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures
2 Nephrogenic Systemic Fibrosis GBCAs increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs
The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing

Known Side Effects

8 documented side effects by frequency

Nausea

>10%

Itching

>10%

Vomiting

1-10%

Rash

1-10%

Shortness of Breath

0.1-1%

Dizziness

0.1-1%

Headache

0.1-1%

Tingling/Numbness

0.1-1%

Community Discussions

No community discussions found for GADOPICLENOL yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → GADOPICLENOL openFDA label JSON → GADOPICLENOL FAERS adverse-event reports → GADOPICLENOL ClinicalTrials.gov → completed Phase 2+ trials of GADOPICLENOL

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous